uniQure (QURE) CEO Matthew Kapusta Buys $1.2M of Stock
Matthew Kapusta, CEO of uniQure N.V., purchases a significant number of shares amidst recent trading activity.
Reviewed by automated data checks against the source filing. How we make and check alerts
Matthew Kapusta, CEO, Managing Director at uniQure N.V. ($QURE), bought 62,581 shares at an average price of $19.39, worth about $1.21 million, on June 17, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $QURE is up 1.4% after 1 week, down 16.4% after 1 month and down 54.8% to date (from the $48.16 close on Jun 17, 2026).
QURE
uniQure N.V.
Key Points
- On June 17, 2026, CEO Matthew Kapusta bought 62,581 shares of uniQure N.V. for about $1.21 million at an average price of $19.39 each.
- The stock closed at $45.77 on the day of the purchase, well above its 52-week low of $8.73, but significantly lower than its 52-week high of $71.50.
- Analysts maintain a strong buy consensus for uniQure, with a mean price target of $61.46 based on 12 opinions.
Get $QURE trade alerts by text
We text you when insiders, Congress or big funds trade $QURE. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated uniQure N.V. alert may contain errors. Disclosures
CEO's Significant Purchase
On June 17, 2026, Matthew Kapusta, the CEO of uniQure N.V. (NasdaqGS: QURE), bought 62,581 shares for approximately $1.21 million. He purchased these shares at an average price of $19.39 each. This transaction shows Kapusta's confidence in the company, especially as it follows his earlier trades in the same month.
Recent Insider Activity
This purchase by Kapusta is part of a pattern of recent insider transactions. Just a few days prior, on June 24, 2026, he bought 4,128 shares at $31.71 each. Earlier the same day, he also sold 4,128 shares. On June 26, Chief Medical Officer Walid Abi-Saab sold 1,434 shares for $67,197.24, further indicating ongoing activity among the executive team.
How uniQure N.V. Stock Has Traded
The stock price of uniQure closed at $45.77 on the day of Kapusta's purchase, which is significantly above its 52-week low of $8.73 but below its 52-week high of $71.50. This suggests that the stock has experienced considerable volatility, trading well below its previous highs. The recent share price reflects investor sentiment and market conditions.
Analysts Set New Price Targets
Analysts have a generally positive outlook on uniQure. On October 5, 2026, Barclays downgraded the stock to an Equal-Weight rating with a target of $28.00, down from $60.00. However, RBC Capital maintained its Outperform rating with a target of $48.00 on October 2, 2026. Other firms like Goldman Sachs and Wells Fargo have also provided ratings, with targets ranging from $31.00 to $75.00. The consensus suggests a strong buy with a mean price target of $61.46 based on 12 analyst opinions.
What uniQure N.V. Does
uniQure N.V. develops innovative gene therapies for rare diseases. Its flagship product, HEMGENIX, helps patients with hemophilia B. The company is also advancing several gene therapy candidates for conditions like Huntington's disease and ALS. Kapusta's recent investments signal confidence in the company's future prospects as it continues to develop its pipeline.
What's Ahead for uniQure N.V.
Investors will be watching for the next earnings report scheduled for November 9, 2026. This report could provide further insights into the company's performance and future plans. Keep in mind that insider transactions and analyst ratings can change, reflecting the dynamic nature of the market and the company's position within it. Remember, the recent insider buying reflects past positions and may not represent current holdings.
Related Filing Alerts
Source: Matthew Kapusta's Form 4 filing on $QURE (Jun 17, 2026). Find the original filing: QURE Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts